Perret J, Feuerstein C, Pellat J, Serre F, Gavend M, Tanche M
Rev Neurol (Paris). 1977 Nov;133(11):627-36.
Horary plasmatic dosages of Dopa and metabolites in 30 treated parkinsonian patients have shown that, within the group of patients treated with L-Dopa combined with an extracerebral decarboxylase inhibitor, highly significant by increased plasmatic O-methyl-dopa levels can be found in patients with dyskinesias compared with those without dyskinesias. On the contrary, in these two subgroups of patients, plasmatic Dopa levels are not significantly different. By comparing some favoured Dopa and O-methyl-dopa levels between these two subgroups of patients, it seems more likely, that the elevated plasmatic O-methyl-dopa levels are due to an progressive accumulation on of its compound than to an excessive formation from Dopa.
对30例接受治疗的帕金森病患者进行的多巴及其代谢产物的即时血浆剂量测定表明，在接受左旋多巴联合脑外脱羧酶抑制剂治疗的患者组中，与无运动障碍的患者相比，有运动障碍的患者血浆O-甲基多巴水平显著升高。相反，在这两个亚组患者中，血浆多巴水平无显著差异。通过比较这两个亚组患者中一些理想的多巴和O-甲基多巴水平，似乎更有可能的是，血浆O-甲基多巴水平升高是由于其化合物的逐渐积累，而不是多巴的过度形成。
